Dan­ish biotech gears up for Phase IIb hidradeni­tis sup­pu­ra­ti­va tri­al fol­low­ing ear­ly clin­i­cal re­sults

MC2 Ther­a­peu­tics’ drug can­di­date for hidradeni­tis sup­pu­ra­ti­va has shown hints of ef­fi­ca­cy po­ten­tial in a Phase IIa tri­al, spark­ing plans for Phase IIb de­vel­op­ment with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER